Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL793141 | 0.98 | DRD2 (1.00) | DRD2HTR1ADRD4HTR2AHTR2C | |
| SCHEMBL7134140 | 0.94 | DRD2 (0.98) | DRD2HTR1ADRD4HTR2AHTR2C | |
| SCHEMBL15064308 | 0.94 | DRD2 (0.89) | DRD2HTR1ADRD4HTR2AHTR2C | |
| SCHEMBL15064479 | 0.89 | DRD2 (0.98) | DRD2HTR1ADRD4HTR2AHTR2C | |
| SCHEMBL792611 | 0.86 | DRD2 (0.94) | DRD2HTR1ADRD4HTR2AHTR2C | |
| SCHEMBL5392500 | 0.86 | DRD2 (0.75) | DRD2HTR1ADRD4HTR2AHTR2C | |
| SCHEMBL5387582 | 0.85 | DRD2 (0.75) | DRD2HTR1ADRD4HTR2AHTR2C | |
| SCHEMBL790948 | 0.84 | DRD2 (0.72) | DRD2HTR1ADRD4HTR2AHTR2C | |
| SCHEMBL5389927 | 0.84 | DRD2 (0.75) | DRD2HTR1ADRD4HTR2AHTR2C | |
| SCHEMBL791945 | 0.83 | DRD2 (0.70) | DRD2HTR1ADRD4HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120767-B2 | Arylosulfonamides for the treatment of CNS diseases | ADAMED SP. Z.O.O. (PL) | 2015-09-01 | — | — | US | disclosed |
| US-20140336200-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z O.O. (PL) | 2014-11-13 | — | — | US | disclosed |
| US-8822517-B2 | Arylosulfonamides for the treatment of CNS diseases | ADAMED SP. Z O.O. (PL) | 2014-09-02 | — | — | US | disclosed |
| US-20130172365-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z.O.O. (PL) | 2013-07-04 | — | — | US | disclosed |
| EP-2044029-B1 | TARTRATE SALT OF (7S)-7-[(5-FLUORO-2-METHYL-BENZYL)OXY]-2-[(2R)-2-METHYLPIPERAZIN-1-YL]-6,7-DIHYDRO-5H-CYCLOPENTA[B]PYRIDINE | PFIZER PROD INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100004259-A1 | Tartrate Salt of (7S)-7-[(5-Fluoro-2-Methyl-Benzyl)oxy]-2-[(2R)-2-Methylpiperazin-1-YL]-6,7-Dihydro-5H-Cyclopenta[B]Pyridine | PFIZER INC. | 2010-01-07 | — | — | US | disclosed |
| US-7507732-B2 | Cyclopentapyridine and tetrahydroquinoline derivatives | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080045512-A1 | Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
| US-20060247254-A1 | Cyclopentapyridine and tetrahydroquinoline derivatives | PFIZER. INC | 2006-11-02 | — | — | US | disclosed |
| US-20060173179-A1 | Azabenzoxazoles for the treatment of CNS disorders | PFIZER INC | 2006-08-03 | — | — | US | disclosed |
| US-20060166974-A1 | Azabenzoxazoles for the treatment of CNS disorders | PFIZER INC. | 2006-07-27 | — | — | US | disclosed |
| US-20050215571-A1 | Therapeutic combination for cognititon enhancement and psychotic disorders | PFIZER INC. | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336200-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ARSA, PMP22, STS | DRD2 3216/4885HTR1A 1354/4885DRD4 3761/4885 |
| US-20050215571-A1 | Therapeutic combination for cognititon enhancement and psychotic disorders | CHRNA3, CHRNA7, CHRNA2 | DRD2 45/4885HTR1A 91/4885DRD4 90/4885 |
| US-20060166974-A1 | Azabenzoxazoles for the treatment of CNS disorders | CHRNA7, CHRNA5, CHRNA10 | DRD2 798/4885HTR1A 131/4885DRD4 857/4885 |
| US-20060247254-A1 | Cyclopentapyridine and tetrahydroquinoline derivatives | HTR2C, HTR2A, HTR5A | DRD2 71/4885HTR1A 8/4885DRD4 216/4885 |
| US-20060173179-A1 | Azabenzoxazoles for the treatment of CNS disorders | CHRNA7, CHRNA5, CHRNA10 | DRD2 759/4885HTR1A 121/4885DRD4 795/4885 |
| US-20130172365-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ARSA, PMP22, STS | DRD2 3216/4885HTR1A 1354/4885DRD4 3761/4885 |
| US-20100004259-A1 | Tartrate Salt of (7S)-7-[(5-Fluoro-2-Methyl-Benzyl)oxy]-2-[(2R)-2-Methylpiperazin-1-YL]-6,7-Dihydro-5H-Cyclopenta[B]Pyridine | HTR2C, HTR5A, HTR7 | DRD2 262/4885HTR1A 5/4885DRD4 400/4885 |
| US-20080045512-A1 | Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane | GABRA5, SLC6A3, GABRA1 | DRD2 546/4885HTR1A 594/4885DRD4 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.